{"id":"guanadrel","rwe":[{"pmid":"36709428","year":"2023","title":"Highlights in TMPRSS2 inhibition mechanism with guanidine derivatives approved drugs for COVID-19 treatment.","finding":"","journal":"Journal of biomolecular structure & dynamics","studyType":"Clinical Study"},{"pmid":"11527735","year":"2001","title":"N-hydroxyl derivatives of guanidine based drugs as enzymatic NO donors.","finding":"","journal":"Bioorganic & medicinal chemistry letters","studyType":"Clinical Study"},{"pmid":"8203510","year":"1994","title":"Arterial alpha-adrenergic responsiveness is decreased and SNS activity is increased in older humans.","finding":"","journal":"The American journal of physiology","studyType":"Clinical Study"},{"pmid":"8473492","year":"1993","title":"Homologous upregulation of human arterial alpha-adrenergic responses by guanadrel.","finding":"","journal":"The Journal of clinical investigation","studyType":"Clinical Study"},{"pmid":"1443127","year":"1992","title":"Hypertension and insulin resistance: role of sympathetic nervous system activity.","finding":"","journal":"The American journal of physiology","studyType":"Clinical Study"}],"tags":[{"label":"guanadrel","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Alpha-1A adrenergic receptor","category":"target"},{"label":"ADRA1A","category":"gene"},{"label":"SLC6A2","category":"gene"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Hypertensive disorder","category":"indication"},{"label":"Pharmacia And Upjohn","category":"company"},{"label":"Approved 1980s","category":"decade"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=GUANADREL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:26:34.321296+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:26:39.702854+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GUANADREL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:26:40.061305+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1037/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:26:40.752592+00:00"}},"allNames":"hylorel","offLabel":[],"synonyms":["hylorel","guanadrel","guanadrel sulfate"],"timeline":[{"date":"1982-12-29","type":"positive","source":"DrugCentral","milestone":"FDA approval (Pharmacia And Upjohn)"}],"aiSummary":"Hylorel (Guanadrel) is a small molecule drug developed by Pharmacia and Upjohn that targets the alpha-1A adrenergic receptor. It is classified as a guanadrel and was FDA approved in 1982 for the treatment of hypertensive disorders. As an off-patent medication, there are currently no generic manufacturers. Key safety considerations include its potential effects on blood pressure and heart rate. Hylorel is a vasodilator that works by blocking the alpha-1A adrenergic receptor, leading to decreased peripheral resistance and lowered blood pressure.","approvals":[{"date":"1982-12-29","orphan":false,"company":"PHARMACIA AND UPJOHN","regulator":"FDA"}],"brandName":"Hylorel","ecosystem":[{"indication":"Hypertensive disorder","otherDrugs":[{"name":"acebutolol","slug":"acebutolol","company":"Promius Pharma"},{"name":"aliskiren","slug":"aliskiren","company":"Novartis"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"}],"globalPrevalence":null}],"mechanism":{"target":"Alpha-1A adrenergic receptor","novelty":"Follow-on","targets":[{"gene":"ADRA1A","source":"DrugCentral","target":"Alpha-1A adrenergic receptor","protein":"Alpha-1A adrenergic receptor"},{"gene":"SLC6A2","source":"DrugCentral","target":"Sodium-dependent noradrenaline transporter","protein":"Sodium-dependent noradrenaline transporter"}],"modality":"Small Molecule","drugClass":"guanadrel","explanation":"","oneSentence":"","technicalDetail":"Hylorel (Guanadrel) is a selective alpha-1A adrenergic receptor antagonist that competes with norepinephrine for binding sites on the receptor, resulting in decreased sympathetic tone and vasodilation."},"commercial":{"launchDate":"1982","_launchSource":"DrugCentral (FDA 1982-12-29, PHARMACIA AND UPJOHN)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1339","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GUANADREL","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T14:56:59.581511","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:26:42.373212+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"amfetamine","drugSlug":"amfetamine","fdaApproval":"1955-09-09","relationship":"same-target"},{"drugName":"amiodarone","drugSlug":"amiodarone","fdaApproval":"1985-12-24","patentExpiry":"Mar 13, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amitriptyline","drugSlug":"amitriptyline","fdaApproval":"1961-04-07","genericCount":33,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amoxapine","drugSlug":"amoxapine","fdaApproval":"1980-09-22","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"aripiprazole","drugSlug":"aripiprazole","fdaApproval":"2002-11-15","patentExpiry":"Sep 24, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"astemizole","drugSlug":"astemizole","fdaApproval":"1988-12-31","relationship":"same-target"},{"drugName":"atomoxetine","drugSlug":"atomoxetine","fdaApproval":"2002-11-26","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"benzatropine","drugSlug":"benzatropine","fdaApproval":"1954-03-05","relationship":"same-target"},{"drugName":"benzethonium","drugSlug":"benzethonium","fdaApproval":"","relationship":"same-target"},{"drugName":"benzphetamine","drugSlug":"benzphetamine","fdaApproval":"1960-10-26","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"genericName":"guanadrel","indications":{"approved":[{"name":"Hypertensive disorder","source":"DrugCentral","snomedId":38341003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"amfetamine","brandName":"amfetamine","genericName":"amfetamine","approvalYear":"1955","relationship":"same-target"},{"drugId":"amiodarone","brandName":"amiodarone","genericName":"amiodarone","approvalYear":"1985","relationship":"same-target"},{"drugId":"amitriptyline","brandName":"amitriptyline","genericName":"amitriptyline","approvalYear":"1961","relationship":"same-target"},{"drugId":"amoxapine","brandName":"amoxapine","genericName":"amoxapine","approvalYear":"1980","relationship":"same-target"},{"drugId":"aripiprazole","brandName":"aripiprazole","genericName":"aripiprazole","approvalYear":"2002","relationship":"same-target"},{"drugId":"astemizole","brandName":"astemizole","genericName":"astemizole","approvalYear":"1988","relationship":"same-target"},{"drugId":"atomoxetine","brandName":"atomoxetine","genericName":"atomoxetine","approvalYear":"2002","relationship":"same-target"},{"drugId":"benzatropine","brandName":"benzatropine","genericName":"benzatropine","approvalYear":"1954","relationship":"same-target"},{"drugId":"benzethonium","brandName":"benzethonium","genericName":"benzethonium","approvalYear":"","relationship":"same-target"},{"drugId":"benzphetamine","brandName":"benzphetamine","genericName":"benzphetamine","approvalYear":"1960","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000179147","MMSL":"1821","NDDF":"000641","UNII":"765C9332T4","VUID":"4019769","CHEBI":"CHEBI:5555","VANDF":"4018079","INN_ID":"2590","RXNORM":"217653","UMLSCUI":"C0061938","chemblId":"CHEMBL1037","ChEMBL_ID":"CHEMBL1037","KEGG_DRUG":"D00607","DRUGBANK_ID":"DB00226","PUBCHEM_CID":"38521","SNOMEDCT_US":"14013006","IUPHAR_LIGAND_ID":"7193","SECONDARY_CAS_RN":"22195-34-2","MESH_SUPPLEMENTAL_RECORD_UI":"C004945"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1982-","companyName":"Pharmacia And Upjohn","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"85%"},"publicationCount":34,"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"originalDeveloper":"Pharmacia And Upjohn","recentPublications":[{"date":"2023","pmid":"36709428","title":"Highlights in TMPRSS2 inhibition mechanism with guanidine derivatives approved drugs for COVID-19 treatment.","journal":"Journal of biomolecular structure & dynamics"},{"date":"2001 Sep 3","pmid":"11527735","title":"N-hydroxyl derivatives of guanidine based drugs as enzymatic NO donors.","journal":"Bioorganic & medicinal chemistry letters"},{"date":"1994 May","pmid":"8203510","title":"Arterial alpha-adrenergic responsiveness is decreased and SNS activity is increased in older humans.","journal":"The American journal of physiology"},{"date":"1993 Apr","pmid":"8473492","title":"Homologous upregulation of human arterial alpha-adrenergic responses by guanadrel.","journal":"The Journal of clinical investigation"},{"date":"1992 Nov","pmid":"1443127","title":"Hypertension and insulin resistance: role of sympathetic nervous system activity.","journal":"The American journal of physiology"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"1982","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1982-12-29T00:00:00.000Z","mah":"PHARMACIA AND UPJOHN","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:26:42.373212+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}